Emerging Evidence for Glucagon-like Peptide-1 Agonists in Slowing Chronic Kidney Disease Progression

Overview

Journal Curr Opin Nephrol Hypertens

Specialties Cardiology & Vascular Diseases
Nephrology

Date 2024 Feb 27

PMID 38411162

Authors

Michael W Holliday Jr

Livia Frost

Sankar D Navaneethan

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Diabetic kidney disease continues to increase, and several novel therapeutic agents have been shown to slow the progression of chronic kidney disease in those with diabetes. This review summarizes more recent data on the role of glucagon-like peptide-1 (GLP-1) receptor agonists and kidney outcomes.

Recent Findings: Posthoc analysis of cardiovascular outcome trials, as well as several retrospective studies, demonstrate benefits of GLP-1 receptor agonist therapy for chronic kidney disease progression in diabetics. Although limited randomized clinical trials evidence assessing the effects of GLP-1 receptor agonists on kidney outcomes in diabetic chronic kidney disease patients have been published, FLOW-CKD trial was halted based on interim data for efficacy, and results are awaited.

Summary: GLP-1 receptor agonism is a promising therapy for slowing the progression of diabetic chronic kidney disease. Recent studies support kidney benefits GLP-1 receptor agonists over insulin and dipeptidyl peptidase-4-inhibitors, and the FLOW-CKD trial would inform the potential benefits for reducing the need for dialysis and kidney-disease related mortality in those with kidney disease.

Citing Articles

GLP-1 receptor agonists-another promising therapy for Alport syndrome?.

Boeckhaus J, Mabillard H, Sayer J J Rare Dis (Berlin). 2025; 4(1):5.

PMID: 40026358 PMC: 11870915. DOI: 10.1007/s44162-024-00065-8.

Integrated, person-centred care for patients with complex cardiovascular disease, diabetes mellitus and chronic kidney disease: a randomized trial.

Even G, Stenfors T, Jacobson S, Jernberg T, Franzen-Dahlin A, Jaghult S Clin Kidney J. 2024; 17(11):sfae331.

PMID: 39569316 PMC: 11577277. DOI: 10.1093/ckj/sfae331.

Obesity Medications and Their Impact on Cardiovascular Health: A Narrative Review.

Islam K, Islam R, Tong V, Shami M, Allen K, Brodtmann J Cureus. 2024; 16(10):e71875.

PMID: 39559664 PMC: 11573306. DOI: 10.7759/cureus.71875.

Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.

Quagliariello V, Canale M, Bisceglia I, Iovine M, Giordano V, Giacobbe I Int J Mol Sci. 2024; 25(20).

PMID: 39457081 PMC: 11508560. DOI: 10.3390/ijms252011299.

References

Grunvald E, Shah R, Hernaez R, Chandar A, Pickett-Blakely O, Teigen L . AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022; 163(5):1198-1225. DOI: 10.1053/j.gastro.2022.08.045. View

. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022; 400(10365):1788-1801. PMC: 7613836. DOI: 10.1016/S0140-6736(22)02074-8. View

Peng Z, Yang C, Lin W, Yao W, Ou H, Kuo S . Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study. Cardiovasc Diabetol. 2023; 22(1):272. PMC: 10552437. DOI: 10.1186/s12933-023-01991-5. View

Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View

Navaneethan S, Zoungas S, Caramori M, Chan J, Heerspink H, Hurst C . Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Ann Intern Med. 2020; 174(3):385-394. DOI: 10.7326/M20-5938. View

Rossing P, Baeres F, Bakris G, Bosch-Traberg H, Gislum M, Gough S . The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023; 38(9):2041-2051. PMC: 10469096. DOI: 10.1093/ndt/gfad009. View

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

Lin Y, Wang T, Tsai M, Wu V, Tseng C, Lin M . The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovasc Diabetol. 2023; 22(1):60. PMC: 10024371. DOI: 10.1186/s12933-023-01793-9. View

ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S191-S202. PMC: 9810467. DOI: 10.2337/dc23-S011. View

10.

Michos E, Bakris G, Rodbard H, Tuttle K . Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Am J Prev Cardiol. 2023; 14:100502. PMC: 10258236. DOI: 10.1016/j.ajpc.2023.100502. View

11.

. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102(5S):S1-S127. DOI: 10.1016/j.kint.2022.06.008. View

12.

Nauck M, Niedereichholz U, Ettler R, Holst J, Orskov C, Ritzel R . Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997; 273(5):E981-8. DOI: 10.1152/ajpendo.1997.273.5.E981. View

13.

Trujillo J . Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020; 45 Suppl 1:43-60. PMC: 7540535. DOI: 10.1111/jcpt.13225. View

14.

Chen J, Wu C, Jenq C, Lee T, Tsai C, Tu H . Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease. JAMA Netw Open. 2022; 5(3):e221169. PMC: 8902651. DOI: 10.1001/jamanetworkopen.2022.1169. View

15.

Virani S, Newby L, Arnold S, Bittner V, Brewer L, Demeter S . 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 148(9):e9-e119. DOI: 10.1161/CIR.0000000000001168. View

16.

Wilding J, Batterham R, Calanna S, Davies M, Van Gaal L, Lingvay I . Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384(11):989-1002. DOI: 10.1056/NEJMoa2032183. View

17.

Sattar N, Lee M, Kristensen S, Branch K, Del Prato S, Khurmi N . Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021; 9(10):653-662. DOI: 10.1016/S2213-8587(21)00203-5. View

18.

Schechter M, Cohen C, Fishkin A, Rozenberg A, Yanuv I, Sehtman-Shachar D . Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. Cardiovasc Diabetol. 2023; 22(1):126. PMC: 10225085. DOI: 10.1186/s12933-023-01829-0. View

19.

Wexler D, de Boer I, Ghosh A, Younes N, Bebu I, Inzucchi S . Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. JAMA Intern Med. 2023; 183(7):705-714. PMC: 10203973. DOI: 10.1001/jamainternmed.2023.1487. View

20.

Heerspink H, Sattar N, Pavo I, Haupt A, Duffin K, Yang Z . Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022; 10(11):774-785. DOI: 10.1016/S2213-8587(22)00243-1. View